About US
Contact us
-
Johnson & Johnson scores 60-day stay in high-profile talc litigation: reportAs Johnson & Johnson faces tens of thousands of lawsuits alleging its talc products caused users to develop cancer, a bankruptcy judge has granted the company a temporary reprieve. U.2021/11/12
-
Merck inks yet another $1B-plus supply deal for COVID pill, this time with JapanMerck & Co.'s positive data for oral COVID-19 antiviral molnupiravir continue to pay off in a big way. Wednesday, just a day after unveiling a $1 billion sale order to the U.S., the company discl2021/11/12
-
Moderna, U.S. clash in patent dispute over origins of COVID-19 vaccine: reportThe public/private partnership between the U.S. government and Moderna to quickly develop a COVID-19 vaccine has been lauded as a feel-good success story—and a blueprint for future health crises. But2021/11/10
-
AstraZeneca, FibroGen hope to keep their roxadustat dream alive with new FDA meetingAfter an FDA cold shoulder, FibroGen and partner AstraZeneca still aim to pave a way to market for anemia therapy roxadustat—even if it means conducting another clinical trial. The two companies are2021/11/10
-
AstraZeneca creates unit to handle its COVID-19 vaccines, antibody treatmentsAs AstraZeneca suffered a series of missteps in the development, manufacture and distribution of its COVID-19 vaccine, other companies surged ahead in the race to provide shots to the world.2021/11/8
-
Johnson & Johnson scores reversal of landmark $465M opioid ruling in OklahomaFor years, Johnson & Johnson has been battling lawsuits alleging it played a role in creating the nationwide opioid epidemic. On Tuesday, just days after a high-profile trial win, the company sco2021/11/8
-
Johnson & Johnson, AbbVie, Teva and Endo score industry's first opioid trial winAs U.S. opioid litigation has evolved in recent years, drugmakers have watched the backlog of lawsuits grow as they've consistently failed to pick up any trial wins. This week in California, four com2021/11/3
-
Once sidelined, Eli Lilly's COVID-19 antibody treatment is on the comeback trail with new $1.3B supply agreementAfter a two-month hiatus, Eli Lilly’s COVID-19 antibody treatment is back in the game and hoping for a successful second chapter. On Tuesday, the companyrevealedthat it's has struck a dea2021/11/3
-
Incyte combats insurance hurdles for eczema cream Opzelura, but dermatologists fully on board: execIncyte’s Opzelura (ruxolitinib)cream to treat atopic dermatitis came to market with a classwide black box warning about potential side effects from JAK inhibitors.But to hear the company tell it, der2021/11/1
-
Merck refiles $11.5B Acceleron deal with the FTC. But extending regulators' review time only one benefitMerck & Co.’s $11.5 billion bid for Acceleron Pharma is hitting a delay just as activist investors threaten to derail the deal altogether. Merck has withdrawn its notification of the Acceleron2021/11/1